Therefore, the use of CSF1R and CSF1 inhibitors in glioma might have differential effects, as the downstream signaling events triggered by CSF1 and IL‐34 are distinct (Chihara et al, 2010; Barve et al, 2013). This evidence concerns the gene IL34 and central nervous system cancer.